Aquatox in ontwikkeling handzweten en okselzweten

[Thijs]

Aquatox (DTX-023) is an investigational, highly purified 900 kDa botulinum toxin type A developed by Aquavit Holdings for treating primary axillary and palmar hyperhidrosis. As of April 2023, the company received FDA approval to proceed with Phase 2/3 clinical trials. It acts as a neuromodulator to temporarily block sweat-producing nerve signals.
Key Aspects of Aquatox for Hyperhidrosis:
Target Conditions: Specifically being studied for severe primary axillary (underarm) and palmar (hand) hyperhidrosis.
Mechanism: It is a potent neurotoxin derived from Clostridium botulinum that inhibits the release of acetylcholine, which activates sweat glands.
Development Stage: In 2023, Aquavit Holdings filed Investigational New Drug (IND) applications and initiated studies for this specialized, purified toxin.
Comparison to Alternatives: Unlike the established use of Botox (onabotulinumtoxinA), Aquatox is a newer candidate in the pipeline focusing on providing a targeted, highly purified option.
While other treatments like BOTOX® are FDA-approved, providing 6-12 months of relief, Aquatox aims to offer another effective injectable solution to reduce excessive sweating, which often causes significant social anxiety and lifestyle disruption.

Kortom een nieuw soort botox maar dan beter en naast oksels ook voor handen. Kan er weinig over vinden verder maar het is goed dat er nog steeds nieuwe onderzoeken komen.

Check ook

https://dermnppa.org/updates-from-aad-2023/